Cingulate Inc. (CING)

Market Cap	81.98M +497.7%
Revenue (ttm)	n/a
Net Income	-22.45M
EPS	-4.44
Shares Out	11.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	836,256
Open	7.08
Previous Close	7.51
Day's Range	6.60 - 7.99
52-Week Range	3.20 - 11.89
Beta	-0.77
Analysts	Strong Buy
Price Target	37.00 (+424.82%)
Earnings Date	Mar 18, 2026

About CING

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 8, 2021
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: CING
• Website: https://www.cingulate.com

Analyst Summary

According to 2 analysts, the average rating for CING stock is "Strong Buy." The 12-month stock price target is $37.0, which is an increase of 424.82% from the latest price.

Price Target

$37.0

(424.82% upside)

Analyst Consensus: Strong Buy